Please assess the completion status of the following clinical trial:

Trial Title: Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with active ankylosing spondylitis~* BASDAI score ≥ 4 and visual analogue scale(VAS) score of spinal pain ≥ 4~Exclusion Criteria:~* have total ankylosing of spine~* have allergies to infliximab~* serious infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CT-P13 (Type: ACTIVE_COMPARATOR): infliximab
- Remicade (Type: ACTIVE_COMPARATOR): infliximab

Based on this trial design, predict the completion outcome and termination type (if applicable).